Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 19/20 | 0.73 |
| ▸ | MAPK11 | Q15759 | 4/20 | 0.73 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.45 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.45 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.45 |
| ▸ | STRADA | Q7RTN6 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2849955 | 0.88 | MAPK14 (0.62) | MAPK14MAPK11ROCK2MAPK12STRADA | |
| SCHEMBL2849958 | 0.88 | MAPK14 (0.62) | MAPK14MAPK11ROCK2MAPK12STRADA | |
| SCHEMBL9906481 | 0.86 | MAPK14 (0.68) | MAPK14MAPK11ROCK2MAPK12STRADA | |
| SCHEMBL9906462 | 0.86 | MAPK14 (0.70) | MAPK14MAPK11GABRA5ROCK2MAPK12 | |
| SCHEMBL9906464 | 0.86 | MAPK14 (0.70) | MAPK14MAPK11ROCK2MAPK12STRADA | |
| SCHEMBL9906463 | 0.86 | MAPK14 (0.70) | MAPK14MAPK11GABRA5ROCK2MAPK12 | |
| SCHEMBL5320830 | 0.85 | MAPK14 (0.69) | MAPK14MAPK11ROCK2MAPK12STRADA | |
| SCHEMBL2843659 | 0.85 | MAPK14 (0.77) | MAPK14MAPK11ROCK2MAPK12STRADA | |
| SCHEMBL2851670 | 0.85 | MAPK14 (0.68) | MAPK14MAPK11ROCK2MAPK12STRADA | |
| SCHEMBL3520417 | 0.85 | MAPK14 (0.72) | MAPK14MAPK11ROCK2MAPK12STRADA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007081901-A2 | PYRIMIDINONE DERIVATIVES AS PROTEIN KINASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2007-07-19 | — | — | WO | disclosed |